Last reviewed · How we verify
Parathyroid Hormone (PTH)
Parathyroid Hormone (PTH) is a Peptide hormone / PTH1 receptor agonist Small molecule drug developed by Takeda. It is currently FDA-approved for Osteoporosis in postmenopausal women and men at high risk of fracture, Hypoparathyroidism. Also known as: Preotact.
PTH binds to PTH1 receptors on bone and kidney cells to increase serum calcium and phosphate levels, promoting bone formation and mineral homeostasis.
PTH binds to PTH1 receptors on bone and kidney cells to increase serum calcium and phosphate levels, promoting bone formation and mineral homeostasis. Used for Osteoporosis in postmenopausal women and men at high risk of fracture, Hypoparathyroidism.
At a glance
| Generic name | Parathyroid Hormone (PTH) |
|---|---|
| Also known as | Preotact |
| Sponsor | Takeda |
| Drug class | Peptide hormone / PTH1 receptor agonist |
| Target | PTH1 receptor (PTHR1) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone Metabolism |
| Phase | FDA-approved |
Mechanism of action
PTH is an 84-amino acid peptide hormone that acts as a G-protein coupled receptor agonist at the PTH1 receptor. In bone, it stimulates osteoblasts to increase bone formation when administered intermittently, while in the kidney it enhances calcium reabsorption and phosphate excretion. This dual action restores calcium-phosphate balance and increases bone mineral density.
Approved indications
- Osteoporosis in postmenopausal women and men at high risk of fracture
- Hypoparathyroidism
Common side effects
- Nausea
- Headache
- Dizziness
- Injection site reactions
- Hypercalcemia
Key clinical trials
- A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
- Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors (PHASE2, PHASE3)
- Natural History Study of Parathyroid Disorders
- PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery" (NA)
- Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study (NA)
- Thyroidectomy: Microscopic Versus Conventional (NA)
- Radiofrequency Ablation For Recurrent Parathyroid Carcinoma (NA)
- TumorGlow Intraoperative Molecular Imaging (IMI) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parathyroid Hormone (PTH) CI brief — competitive landscape report
- Parathyroid Hormone (PTH) updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Parathyroid Hormone (PTH)
What is Parathyroid Hormone (PTH)?
How does Parathyroid Hormone (PTH) work?
What is Parathyroid Hormone (PTH) used for?
Who makes Parathyroid Hormone (PTH)?
Is Parathyroid Hormone (PTH) also known as anything else?
What drug class is Parathyroid Hormone (PTH) in?
What development phase is Parathyroid Hormone (PTH) in?
What are the side effects of Parathyroid Hormone (PTH)?
What does Parathyroid Hormone (PTH) target?
Related
- Drug class: All Peptide hormone / PTH1 receptor agonist drugs
- Target: All drugs targeting PTH1 receptor (PTHR1)
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Endocrinology / Bone Metabolism
- Indication: Drugs for Osteoporosis in postmenopausal women and men at high risk of fracture
- Indication: Drugs for Hypoparathyroidism
- Also known as: Preotact
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing